CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Applied Therapeutics Inc - APLT CFD

7.6970
0.13%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0360
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024901 %
Charges from full value of position ($-4.73)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024901%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002679 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002679%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 7.687
Open 7.717
1-Year Change 251.4%
Day's Range 7.567 - 8.017
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 4, 2024 7.6870 -0.2300 -2.91% 7.9170 8.0070 7.5570
Oct 3, 2024 7.8470 -0.4500 -5.42% 8.2970 8.3270 7.6370
Oct 2, 2024 8.3770 0.1100 1.33% 8.2670 8.5670 8.1470
Oct 1, 2024 8.3770 0.0100 0.12% 8.3670 8.6170 8.0670
Sep 30, 2024 8.4970 0.2800 3.41% 8.2170 8.8470 8.1370
Sep 27, 2024 8.2570 -0.1600 -1.90% 8.4170 8.5970 8.1370
Sep 26, 2024 8.3970 -0.0700 -0.83% 8.4670 8.7670 8.1970
Sep 25, 2024 8.3570 0.3600 4.50% 7.9970 8.5770 7.9970
Sep 24, 2024 8.0870 0.4800 6.31% 7.6070 8.2270 7.4870
Sep 23, 2024 7.6670 -0.0200 -0.26% 7.6870 8.0870 7.5870
Sep 20, 2024 7.6970 -0.2000 -2.53% 7.8970 8.3270 7.5170
Sep 19, 2024 7.9770 -0.0100 -0.13% 7.9870 8.8370 7.8170
Sep 18, 2024 7.8370 1.3200 20.25% 6.5170 8.3770 6.4470
Sep 17, 2024 4.6370 -0.0100 -0.22% 4.6470 4.7670 4.6070
Sep 16, 2024 4.6770 -0.2100 -4.30% 4.8870 4.9670 4.5370
Sep 13, 2024 4.8770 -0.0100 -0.20% 4.8870 4.9270 4.5970
Sep 12, 2024 4.8670 -0.2600 -5.07% 5.1270 5.3670 4.8370
Sep 11, 2024 5.1870 0.0500 0.97% 5.1370 5.3570 4.9870
Sep 10, 2024 5.1784 -0.4800 -8.48% 5.6584 5.7284 5.1284
Sep 9, 2024 5.7484 0.0600 1.05% 5.6884 5.9784 5.6884

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Applied Therapeutics, Inc. Company profile

About Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Applied Therapeutics Inc revenues was not reported. Net loss increased 12% to $105.6M. Higher net loss reflects General and administrative - Balancing increase of 66% to $15.7M (expense), Stock-based Compensation in SGA increase of 55% to $8.4M (expense), Other general & administrative expenses increase of 73% to $5.4M (expense).

Industry: Bio Therapeutic Drugs

545 5Th Avenue, Suite 1400
NEW YORK
NEW YORK 10017
US

News

Gold's recent Story

Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.

15:36, 7 October 2024

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

Market of the Month - Gold, an overview

In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.

06:00, 30 September 2024

RBA Preview: Rates to remain unchanged with inflation-fighting still the focus

RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.

12:27, 20 September 2024

BoE Preview: no change expected but forward guidance will be key

The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.

14:53, 19 September 2024

FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion

Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.

11:30, 19 September 2024

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

People also watch

BTC/USD

63,462.75 Price
+1.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Oil - Crude

76.96 Price
+3.760% 1D Chg, %
Long position overnight fee 0.0196%
Short position overnight fee -0.0416%
Overnight fee time 21:00 (UTC)
Spread 0.030

Gold

2,643.99 Price
-0.340% 1D Chg, %
Long position overnight fee -0.0178%
Short position overnight fee 0.0096%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.55 Price
+1.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading